Suppr超能文献

合作国际神经肌肉研究组杜兴氏肌营养不良自然病史研究表明,杜兴氏肌营养不良症患者的心肌病诊断和治疗不足。

Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy.

机构信息

Research Center for Genetic Medicine, Children's National Medical Center, Washington, DC, USA.

出版信息

Muscle Nerve. 2014 Aug;50(2):250-6. doi: 10.1002/mus.24163. Epub 2014 May 14.

Abstract

INTRODUCTION

Cardiomyopathy is a common cause of morbidity and death in patients with Duchenne muscular dystrophy (DMD).

METHODS

This investigation was a cross-sectional cross-sectional analysis of clinical data from the multi-institutional Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study of 340 DMD patients aged 2-28 years. Cardiomyopathy was defined as shortening fraction (SF) <28% or ejection fraction (EF) <55%.

RESULTS

Two hundred thirty-one participants reported a prior clinical echocardiogram study, and 174 had data for SF or EF. The prevalence of cardiomyopathy was 27% (47 of 174), and it was associated significantly with age and clinical stage. The association of cardiomyopathy with age and clinical stage was not changed by glucocorticoid use as a covariate (P > 0.68). In patients with cardiomyopathy, 57% (27 of 47) reported not taking any cardiac medications. Cardiac medications were used in 12% (15 of 127) of patients without cardiomyopathy.

CONCLUSIONS

We found that echocardiograms were underutilized, and cardiomyopathy was undertreated in this DMD natural history cohort.

摘要

简介

心肌病是杜氏肌营养不良症(DMD)患者发病和死亡的常见原因。

方法

本研究对多机构合作国际神经肌肉研究组(CINRG)DMD 自然史研究中的 340 例 2-28 岁 DMD 患者的临床数据进行了横断面分析。心肌病定义为缩短分数(SF)<28%或射血分数(EF)<55%。

结果

231 名参与者报告了先前的临床超声心动图研究,174 名参与者有 SF 或 EF 的数据。心肌病的患病率为 27%(174 例中的 47 例),与年龄和临床分期显著相关。将糖皮质激素的使用作为协变量后,心肌病与年龄和临床分期的相关性没有改变(P>0.68)。在患有心肌病的患者中,57%(47 例中的 27 例)报告未服用任何心脏药物。在没有心肌病的患者中,有 12%(127 例中的 15 例)使用了心脏药物。

结论

我们发现,在这个 DMD 自然史队列中,超声心动图的应用不足,且心肌病的治疗不足。

相似文献

2
Interleukin 1 Receptor-Like 1 Protein (ST2) is a Potential Biomarker for Cardiomyopathy in Duchenne Muscular Dystrophy.
Pediatr Cardiol. 2017 Dec;38(8):1606-1612. doi: 10.1007/s00246-017-1703-9. Epub 2017 Aug 18.
4
Precordial R wave height does not correlate with echocardiographic findings in boys with Duchenne muscular dystrophy.
Congenit Heart Dis. 2013 Nov-Dec;8(6):561-7. doi: 10.1111/chd.12049. Epub 2013 Mar 20.
6
Left ventricular T2 distribution in Duchenne muscular dystrophy.
J Cardiovasc Magn Reson. 2010 Mar 18;12(1):14. doi: 10.1186/1532-429X-12-14.
7
The IAAM LTBP4 Haplotype is Protective Against Dystrophin-Deficient Cardiomyopathy.
J Neuromuscul Dis. 2024;11(2):285-297. doi: 10.3233/JND-230129.
9
Advances in the diagnosis and management of cardiomyopathy in Duchenne muscular dystrophy.
Neuromuscul Disord. 2018 Sep;28(9):711-716. doi: 10.1016/j.nmd.2018.06.014. Epub 2018 Jul 6.
10
Exercise Cardiac Magnetic Resonance Imaging in Boys With Duchenne Muscular Dystrophy Without Cardiac Disease.
Pediatr Neurol. 2021 Apr;117:35-43. doi: 10.1016/j.pediatrneurol.2020.12.011. Epub 2020 Dec 30.

引用本文的文献

3
Prophylactic Use of Cardiac Medications and Survival in Duchenne Muscular Dystrophy.
Muscle Nerve. 2025 Apr;71(4):574-582. doi: 10.1002/mus.28353. Epub 2025 Jan 24.
6
The IAAM LTBP4 Haplotype is Protective Against Dystrophin-Deficient Cardiomyopathy.
J Neuromuscul Dis. 2024;11(2):285-297. doi: 10.3233/JND-230129.

本文引用的文献

1
Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.
J Pediatr. 2013 Oct;163(4):1080-4.e1. doi: 10.1016/j.jpeds.2013.05.060. Epub 2013 Jul 15.
4
All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy.
J Am Coll Cardiol. 2013 Mar 5;61(9):948-54. doi: 10.1016/j.jacc.2012.12.008. Epub 2013 Jan 23.
6
Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy.
Am J Cardiol. 2012 Jul 1;110(1):98-102. doi: 10.1016/j.amjcard.2012.02.064. Epub 2012 Mar 29.
7
Evidence-based path to newborn screening for Duchenne muscular dystrophy.
Ann Neurol. 2012 Mar;71(3):304-13. doi: 10.1002/ana.23528.
8
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.
Lancet Neurol. 2010 Feb;9(2):177-89. doi: 10.1016/S1474-4422(09)70272-8. Epub 2009 Nov 27.
9
Cardiac assessment of patients with late stage Duchenne muscular dystrophy.
Neth Heart J. 2009 Jun;17(6):232-7. doi: 10.1007/BF03086253.
10
Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy.
Neuromuscul Disord. 2008 May;18(5):365-70. doi: 10.1016/j.nmd.2008.03.002. Epub 2008 Apr 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验